Phathom Pharmaceuticals
PHAT
133 hedge funds and large institutions have $1.31B invested in Phathom Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 18 reducing their positions, and 10 closing their positions.
327% more call options, than puts
Call options by funds: $4.5M | Put options by funds: $1.05M
222% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 18
190% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 10
119% more capital invested
Capital invested by funds: $599M → $1.31B (+$714M)
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
17% more funds holding
Funds holding: 114 → 133 (+19)
7.1% more ownership
Funds ownership: 99.27% → 106.36% (+7.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$43.5M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$25M |
| 3 |
O
OrbiMed
New York
|
+$20.3M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$19.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TPC
Takeda Pharmaceutical Company
Tokyo,
Japan
|
-$16M |
| 2 |
6CM
683 Capital Management
New York
|
-$5.45M |
| 3 |
Morgan Stanley
New York
|
-$4.52M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$3.14M |
| 5 |
Two Sigma Investments
New York
|
-$2.09M |
PHAT Hedge Fund Activity: Q3 2024 in Review
133 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q3 2024, worth a combined $1.31B — up 119% from $599M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PHAT positions and 10 closed out — a net gain of 19 holders — while 58 added to existing stakes and 18 trimmed.
The largest buyer was Jennison Associates, adding an estimated $43.5M. The largest seller was Takeda Pharmaceutical Company, exiting entirely with an estimated $16M sold.
- 133 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q3 2024, up from 114 in Q2 2024.
- Funds reported $1.31B of Phathom Pharmaceuticals stock for Q3 2024, up 119% quarter-over-quarter.
- 29 funds opened new Phathom Pharmaceuticals positions in Q3 2024 and 10 closed out, a net change of +19 holders.
- The largest Phathom Pharmaceuticals buyer in Q3 2024 was Jennison Associates, an estimated $43.5M added.
- The largest Phathom Pharmaceuticals seller in Q3 2024 was Takeda Pharmaceutical Company, an estimated $16M sold.
Based on aggregated 13F filings for Q3 2024.